- Home
- ALX vs OPK Comparison
ALX vs OPK Comparison
Compare ALX & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | OPK |
|---|---|---|
| Founded | 1928 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ALX | OPK |
|---|---|---|
| Price | $216.54 | $1.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.28 |
| AVG Volume (30 Days) | 54.7K | ★ 3.3M |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | $215,838,000.00 | ★ $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $184.76 | $1.11 |
| 52 Week High | $260.84 | $2.04 |
Technical Indicators
Market Signals| Indicator | ALX | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 43.99 |
| Support Level | $214.80 | $1.30 |
| Resistance Level | $221.71 | $1.42 |
| Average True Range (ATR) | 4.45 | 0.05 |
| MACD | 1.03 | -0.00 |
| Stochastic Oscillator | 55.20 | 25.16 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.